Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | RRM1 | P23921 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12884734 | 0.85 | PTGS1 (0.56) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL1216829 | 0.83 | PTGS1 (0.54) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL1216833 | 0.83 | PTGS1 (0.54) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL9330023 | 0.81 | ADRA1A (0.43) | DPP7DPP4 | |
| SCHEMBL1337609 | 0.80 | USP2 (0.50) | DPP7RRM1DPP4USP2 | |
| SCHEMBL1337607 | 0.80 | USP2 (0.50) | DPP7RRM1DPP4USP2 | |
| SCHEMBL8034816 | 0.79 | DPP4 (0.46) | DPP7MMP2DPP4USP2 | |
| SCHEMBL2735577 | 0.79 | DPP4 (0.46) | DPP7MMP2DPP4USP2 | |
| SCHEMBL6129730 | 0.78 | DPP7 (0.55) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL20750890 | 0.78 | DPP7 (0.55) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | DPP7 226/4885RRM1 2932/4885GNAI3 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.